Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 65 clinical trials
Safe Accelerated Venetoclax Escalation in CLL (SAVE)

This research study is trying to determine which patients with newly diagnosed or relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), as grouped by their risk for tumor lysis syndrome (TLS), are able to safely tolerate an accelerated, daily venetoclax dose ramp-up rather than the standard approved schedule …

monoclonal protein
chronic lymphocytic leukemia
corticosteroids
rituximab
lymphocytosis
  • 0 views
  • 14 Jun, 2022
  • 1 location
Pneumococcal Pneumonia Vaccine Series (PCV13 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial

This phase II trial tests whether the pneumococcal pneumonia vaccine series (PCV13 and PPSV23) works to mount an effective immune response in patients with chronic lymphocytic leukemia. PCV13 and PPSV23 are both vaccines that protect against bacteria that cause pneumococcal disease. Giving these vaccinations as series may make a stronger …

venetoclax
lymphoma
chronic lymphocytic leukemia
  • 0 views
  • 16 May, 2022
  • 1 location
A Single-arm, Pivotal Registration Phase II Study of the Efficacy and Safety of APG-2575 Monotherapy in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The purpose of this study is to assess the efficacy and safety of APG-2575 single agent in patients with relapsed/refractory CLL/SLL.

  • 0 views
  • 25 Oct, 2022
  • 1 location
A Study on Limiting Treatment Time With Acalabrutinib Combined With Obinutuzumab in People With CLL or SLL

This study will test the safety of limiting treatment time with acalabrutinib and obinutuzumab in people who have chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The researchers want to find out whether stopping the study drugs when the cancer responds to the treatment, followed by a period of …

obinutuzumab
chronic lymphocytic leukemia
anemia
platelet count
neutrophil count
  • 0 views
  • 04 Oct, 2022
  • 7 locations
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax in Combination With Intravenous (IV) Obinutuzumab or Oral Ibrutinib in Adult Participants With Untreated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Chronic lymphocytic leukemia (CLL) is the most common leukemia in Western countries, representing approximately 30% of all adult leukemias. There is a large difference in proportion of malignant lymphoma between the United States (US) and Japan was seen in CLL/small lymphocytic lymphoma (SLL) (Japan, 3.2%; US, 24.1%). The purpose of …

obinutuzumab
venetoclax
chronic lymphocytic leukemia
ibrutinib
lymphoma
  • 0 views
  • 04 Oct, 2022
  • 19 locations
A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL/SLL Patients

This study is being done to test the effectiveness of zanubrutinib in combination with venetoclax in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The names of the study drugs involved in this study are: zanubrutinib (BGB-3111) venetoclax

chronic lymphocytic leukemia
platelet count
lymphoma
acalabrutinib
venetoclax
  • 0 views
  • 11 Oct, 2022
  • 2 locations
Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

This phase II trial tests whether acalabrutinib in combination with venetoclax or obinutuzumab works to shrink tumors in patients with treatment-naive chronic lymphocytic leukemia . Acalabrutinib is also an inhibitor that works in the body to block the activation of certain cells that lead to the growth of cancerous B …

monoclonal protein
chronic lymphocytic leukemia
corticosteroids
cytopenia
rituximab
  • 0 views
  • 07 Oct, 2022
  • 1 location
Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

This is a Phase 1/2, study evaluating IOV-2001 (Adoptive Cell Therapy) composed of autologous PBL (Peripheral Blood Lymphocytes) in patients with CLL/SLL, which has relapsed or is relapsing during treatment with ibrutinib or acalabrutinib.

measurable disease
TP53
chronic lymphocytic leukemia
ibrutinib
acalabrutinib
  • 4 views
  • 21 Mar, 2022
  • 5 locations
Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

This study will find out whether people with CLL or SLL who have received treatment with venetoclax, either alone or in combination with another drug, and who are found to be MRD-negative, can stop treatment with venetoclax and remain off-treatment for 12 months or more. The researchers will also see …

monoclonal protein
chronic lymphocytic leukemia
lymphoid leukemia
lymphoma
venetoclax
  • 25 views
  • 22 Dec, 2021
  • 11 locations
A Study of FCN-338 in Patients With Chronic CLL/SLL

This study is being done to evaluate the TolerabilityPharmacokinetics and Preliminary antitumor activity of oral FCN-338 for the treatment of patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), who have failed or are intolerant to one or more lines of established therapy or for whom no other …

  • 0 views
  • 26 Jan, 2021
  • 1 location